Alyeska Investment Group
RPRX icon

Alyeska Investment Group’s Royalty Pharma RPRX Stock Holding History

Alyeska Investment Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-150,431
Closed -$7.22M – 772
2026
Q1 		$7.22M Buy
+150,431
New +$6.59M 0.02% 435
2025
Q1 		– Sell
-589,848
Closed -$15M – 640
2024
Q4 		$15M Hold
589,848
– – 0.06% 291
2024
Q3 		$16.7M Sell
589,848
-124,556
-17% -$3.45M 0.09% 254
2024
Q2 		$18.8M Sell
714,404
-437,367
-38% -$12.1M 0.11% 219
2024
Q1 		$35M Buy
1,151,771
+130,735
+13% +$3.85M 0.22% 156
2023
Q4 		$28.7M Sell
1,021,036
-207,209
-17% -$5.69M 0.19% 157
2023
Q3 		$33.3M Sell
1,228,245
-192,825
-14% -$5.73M 0.23% 154
2023
Q2 		$43.7M Buy
1,421,070
+782,676
+123% +$26.5M 0.32% 100
2023
Q1 		$23M Buy
638,394
+125,367
+24% +$4.65M 0.2% 142
2022
Q4 		$20.3M Buy
+513,027
New +$21.4M 0.21% 148
2022
Q3 		– Sell
-354,729
Closed -$14.9M – 470
2022
Q2 		$14.9M Buy
354,729
+281,335
+383% +$11.5M 0.17% 173
2022
Q1 		$2.86M Buy
+73,394
New +$2.88M 0.03% 379
2021
Q4 		– Sell
-125,000
Closed -$4.52M – 716
2021
Q3 		$4.52M Sell
125,000
-226,597
-64% -$8.81M 0.06% 348
2021
Q2 		$14.4M Buy
351,597
+25,000
+8% +$1.06M 0.17% 169
2021
Q1 		$14.2M Sell
326,597
-437,220
-57% -$20.7M 0.18% 156
2020
Q4 		$38.2M Buy
763,817
+260,082
+52% +$11M 0.54% 47
2020
Q3 		$21.2M Buy
503,735
+68,540
+16% +$2.94M 0.32% 97
2020
Q2 		$21.1M Buy
+435,195
New +$21.5M 0.32% 113

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group's RPRX Position: Q2 2026 in Review

Alyeska Investment Group sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 150,431 shares — an estimated $7.22M sold.

Alyeska Investment Group first reported a position in RPRX in Q2 2020 and held it in 18 quarters. The position peaked at $43.7M in Q2 2023. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Alyeska Investment Group reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
  • Alyeska Investment Group sold 150,431 Royalty Pharma shares in Q2 2026, an estimated $7.22M.
  • Alyeska Investment Group first reported a position in Royalty Pharma in Q2 2020 and held it in 18 quarters.
  • Alyeska Investment Group's Royalty Pharma position peaked at $43.7M in Q2 2023.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.